Clinical trials · San Francisco, CA
Cancer clinical trials in San Francisco
We’re tracking 483 recruiting cancer studies with a site in or near San Francisco — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near San Francisco
- NCT06606028Recruiting
Blood test for leftover cancer DNA after head and neck cancer treatment
This study uses a simple blood test to look for leftover cancer DNA after treatment for head and neck squamous cell carcinoma. The goal is to see if the test can find very small amounts of cancer early, which might help doctors make better decisions about follow-up care.
San Francisco, CaliforniaAges 18 years+ - NCT06580314RecruitingPhase 3
Olaparib with or without bevacizumab for ovarian cancer
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
San Francisco, CaliforniaAges 18 years+ - NCT05410977Recruiting
Testing blood and stool for colon cancer in Lynch syndrome
This study collects blood and stool samples to see how well they can detect colorectal cancer or advanced growths in people with Lynch syndrome (an inherited colon cancer risk) or suspected Lynch syndrome. It may help find cancer or precancer earlier, which can improve next-step decisions.
San Francisco, CaliforniaAges 18 years+ - NCT06244771RecruitingPhase 1/Phase 2
Testing FMC-376 for KRAS G12C mutated solid tumors
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
San Francisco, CaliforniaAges 18 years+ - NCT06624644RecruitingPhase 2/Phase 3
LNS8801 with or without pembrolizumab for advanced melanoma
This trial tests a new drug called LNS8801, alone or with pembrolizumab, for people with advanced melanoma that has stopped responding to prior treatments, especially anti-PD-1 therapy.
San Francisco, CaliforniaAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT06942104RecruitingPhase 1
New imaging agent for advanced solid tumors
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT06633224Recruiting
Fatigue and biology in cancer patients getting chemoradiation
This study looks at why some people feel very tired during cancer treatment. Researchers will collect blood and stool samples to study how the body responds to chemotherapy and radiation.
San Francisco, CaliforniaAges 18 years+ - NCT06648278Recruiting
Support and technology study for breast cancer patients
This trial tests a program called PONTS 2.0 that uses phone texts and online tools to support breast cancer patients through their treatment. It aims to make it easier for patients to get the help they need.
San Francisco, CaliforniaAges 18 years+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
San Francisco, CaliforniaAges 18 years+ - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
San Francisco, CaliforniaAges 5–60 - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
San Francisco, CaliforniaAges 8 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
San Francisco, CaliforniaAges 18 years+ - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
San Francisco, CaliforniaAges 18 years+ - NCT07100106RecruitingPhase 1/Phase 2
Study of GDC-4198 alone or with giredestrant for advanced breast cancer
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
San Francisco, CaliforniaAges 18 years+ - NCT05232916RecruitingPhase 3
Vaccine for HER2-positive breast cancer after standard treatment
This trial tests a vaccine (GLSI-100) that may help prevent the return of HER2-positive breast cancer. It is given to patients who still had cancer cells after initial treatment with trastuzumab, or who had stage III disease and achieved a complete response.
San Francisco, CaliforniaAges 18–100 - NCT05366699Recruiting
Procedure to help prevent arm swelling after breast surgery
This trial studies a new procedure meant to lower the chance of getting lymphedema (arm swelling) after breast cancer surgery that removes lymph nodes in the armpit. It may help patients reduce the risk of long-term arm swelling, especially after lymph node dissection.
San Francisco, CaliforniaAges 18–75 - NCT06630845Recruiting
Comparing two whole-body scan methods for metastatic cancer
This trial tests whether a newer type of MRI scan (called whole-body DWI) can work as well as a standard PET/CT scan (called FDG PET) for finding and monitoring cancer that has spread. If you have metastatic cancer and already have a scheduled PET/CT or other scan, you may be able to get both scans done, helping researchers compare the two methods.
San Francisco, CaliforniaAges 18 years+ - NCT06445738Recruiting
Can some women safely skip radiation after breast cancer surgery?
This trial is for women 50 and older with early-stage, hormone-positive or HER2-positive breast cancer. It tests whether it is safe to skip radiation therapy after a lumpectomy if an MRI before surgery shows the breast tissue looks a certain way.
San Francisco, CaliforniaAges 50 years+ - NCT06369285RecruitingPhase 2
Alisertib and hormone therapy for advanced breast cancer
This trial tests a new drug, alisertib, combined with hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread or come back and is no longer curable. It may be an option if you've already tried at least two hormone therapies and a CDK4/6 inhibitor.
San Francisco, CaliforniaAges 18 years+ - NCT06613100RecruitingPhase 1
Xaluritamig before prostate surgery for high-risk prostate cancer
This study tests an experimental drug called xaluritamig given before surgery for men with localized prostate cancer that is intermediate or high risk. The goal is to see if it can help shrink the cancer before the prostate is removed.
San Francisco, CaliforniaAges 18 years+ - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
San Francisco, CaliforniaAges Up to 30 years - NCT05208047RecruitingPhase 3
CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
San Francisco, CaliforniaAges 18 years+ - NCT07690579Recruiting
Prostate cancer disparities study
This study looks at how social, lifestyle, and other factors affect prostate cancer outcomes. It enrolls men who have chosen to have their prostate removed (radical prostatectomy) and agreed to join a biobank.
San Francisco, CaliforniaAges 18 years+
Hear when a new Cancer trial opens near San Francisco, CA
We’ll email you when one opens near San Francisco, CA — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near San Francisco
Institutions with a site for the recruiting cancer studies listed above.
- University of California, San Francisco · 18 studies
- Kaiser Permanente-Oakland · 4 studies
- Kaiser Permanente-Vallejo · 4 studies
- Kaiser Permanente San Leandro · 3 studies
- Kaiser Permanente San Rafael · 3 studies
- Kaiser Permanente-San Francisco · 3 studies
- Kaiser Permanente-Santa Teresa-San Jose · 3 studies
- Kaiser Permanente-South San Francisco · 3 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in California.
Common questions
- Are there cancer clinical trials near San Francisco?
- Yes. We're currently tracking 483 recruiting cancer studies with a site near San Francisco, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near San Francisco?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in San Francisco to take part?
- Not necessarily. These studies have a site near San Francisco, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near San Francisco regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.